What Changed at ArteraAI

Artera announced five ASTRO 2026 presentations on its multimodal AI prostate cancer biomarker. One is the first validation in a South Asian population: in the POP-RT trial in India, patients with high MMAI risk had fewer distant metastases with whole pelvis radiation, while intermediate risk patients saw no similar benefit. Another compared risk estimates from commercial testing with STAR-CAP, a database of nearly 20,000 patients, and found them in line with observed outcomes in every NCCN risk group. A third found no evidence of bias by race or age in NRG/RTOG post prostatectomy trials.

Our read

The case for this test has rested mostly on US cooperative group trials. An Indian cohort and a 20,000 patient real world benchmark speak directly to whether the scores hold up outside them.

The ArteraAI Prostate Test was included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer, making it the first AI enabled risk stratification tool recommended in those guidelines. It carries a Level 1B evidence rating under Simon Criteria and a Category 2A recommendation. This followed FDA De Novo marketing authorization in August 2025 and CMS coverage effective January 2024.

Our read

Guideline inclusion is a different class of validation from a vendor claim or even a regulatory clearance, because an independent panel evaluates the underlying evidence and decides whether clinicians should consider the tool at all. For a center weighing AI diagnostics, this is the clearest available answer to the question of whether a test has been assessed by people with no commercial interest in the answer. The specific standing matters: Level 1B evidence under Simon Criteria and a Category 2A recommendation indicating uniform NCCN consensus that the test is a useful option. Note also what the guideline language constrains, since it positions the test as used in addition to NCCN risk category, patient characteristics, and patient preference, which is an externally imposed limit on how far the output may be relied upon.